CLEC-2 Activators
The CLEC-2 Activators represent a collection of diverse chemicals that can indirectly modulate the activity of CLEC-2, a C-type lectin-like receptor that has critical roles in platelet aggregation, and lymphatic vascular development and maintenance. These activators primarily influence cellular signaling pathways that are associated with CLEC-2 activity. The majority of these chemicals modulate intracellular signaling pathways involved in platelet activation and aggregation. For instance, Y-27632, a selective inhibitor of ROCK, and LY294002 and Wortmannin, both inhibitors of PI3K, can affect CLEC-2 mediated platelet activation and aggregation by inhibiting their respective pathways. Similarly, PD98059 and U0126, both inhibitors of MEK, a kinase upstream of ERK, can indirectly modulate CLEC-2 activity by affecting the ERK pathway which is involved in platelet activation and aggregation.
Other chemicals that fall under CLEC-2 Activators are those that disrupt cytoskeletal dynamics, which play a crucial role in platelet activation. Vincristine, Cytochalasin D, and Colchicine, which are inhibitors of microtubule and actin polymerization, can indirectly affect CLEC-2 mediated platelet activation by disrupting the cytoskeletal dynamics. An interesting member of this category is Pomalidomide, an immunomodulatory drug that can downregulate the production of pro-inflammatory cytokines and inhibit angiogenesis. By doing so, it can indirectly modulate the activity of CLEC-2, which also mediates platelet functions and lymphatic vascular development and maintenance. Lastly, BAY 11-7082, an inhibitor of NF-κB activation, belongs to this category as NF-κB is a transcription factor that can regulate the expression of various immune and inflammatory genes, potentially affecting CLEC-2 activity indirectly.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Pomalidomide | 19171-19-8 | sc-364593 sc-364593A sc-364593B sc-364593C sc-364593D sc-364593E | 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $100.00 $143.00 $312.00 $468.00 $1248.00 $1997.00 | 1 | |
Pomalidomide is an immunomodulatory drug that can downregulate the production of pro-inflammatory cytokines and inhibit angiogenesis. By doing so, it can indirectly modulate the activity of CLEC-2, which is known to mediate platelet functions and lymphatic vascular development and maintenance. | ||||||
BAY 11-7085 | 196309-76-9 | sc-202490 sc-202490A | 10 mg 50 mg | $124.00 $526.00 | 55 | |
BAY 11-7082 is an inhibitor of NF-κB activation. As NF-κB is a transcription factor that can regulate the expression of various immune and inflammatory genes, its inhibition can indirectly affect CLEC-2 activity. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a selective inhibitor of ROCK (Rho-associated coiled-coil containing protein kinase). By inhibiting ROCK, it can affect CLEC-2 mediated platelet activation and aggregation as the Rho/ROCK pathway is involved in these processes. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a specific inhibitor of MEK, an upstream activator of ERK. The ERK pathway is indirectly linked with CLEC-2 activity, as it is involved in platelet activation and aggregation, processes which CLEC-2 mediates. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of PI3K. By inhibiting PI3K, it can affect CLEC-2 mediated platelet activation and aggregation as the PI3K pathway is involved in these processes. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. The p38 MAPK pathway is indirectly linked with CLEC-2 activity, as it is involved in platelet activation and aggregation, processes which CLEC-2 mediates. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent and irreversible inhibitor of PI3K. By inhibiting PI3K, it can affect CLEC-2 mediated platelet activation and aggregation as the PI3K pathway is involved in these processes. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $165.00 $486.00 | 64 | |
Cytochalasin D is an actin polymerization inhibitor. Given that actin dynamics are involved in platelet activation, cytochalasin D can indirectly affect CLEC-2 mediated platelet activation. | ||||||
Colchicine | 64-86-8 | sc-203005 sc-203005A sc-203005B sc-203005C sc-203005D sc-203005E | 1 g 5 g 50 g 100 g 500 g 1 kg | $100.00 $321.00 $2289.00 $4484.00 $18207.00 $34749.00 | 3 | |
Colchicine is an agent in research that reduces inflammation by inhibiting microtubule polymerization. Given that microtubule dynamics are involved in platelet activation, colchicine can indirectly affect CLEC-2 mediated platelet activation. | ||||||